ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Subsequent functional characterization shows high-affinity target binding, protease resistance, high plasma stability, inhibition of BCR::ABL1 kinase activity and binding to BCR::ABL1 in CML cell lysates and permeabilized cells.